| Code | CSB-RA023984MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ADG-106, targeting TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as 4-1BB or CD137. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a critical role in enhancing T cell proliferation, survival, and cytotoxic function. Upon engagement with its ligand 4-1BBL, TNFRSF9 delivers potent costimulatory signals that amplify anti-tumor immune responses and promote long-term T cell memory. This pathway has emerged as a promising target in cancer immunotherapy, particularly for solid tumors where enhanced T cell activation is therapeutically beneficial.
ADG-106 represents an agonistic antibody designed to stimulate TNFRSF9 signaling and potentiate anti-tumor immunity in oncology research. This biosimilar antibody provides researchers with a valuable tool for investigating 4-1BB-mediated immune activation, studying T cell costimulation mechanisms, and exploring combination immunotherapy strategies. It supports studies examining tumor microenvironment modulation, T cell exhaustion reversal, and immune checkpoint pathway interactions in various cancer models.
There are currently no reviews for this product.